3,4-methylenedioxyamphetamine has been researched along with Hemolytic-Uremic Syndrome in 1 studies
3,4-Methylenedioxyamphetamine: An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally.
Hemolytic-Uremic Syndrome: A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by hemolytic anemia (ANEMIA, HEMOLYTIC); THROMBOCYTOPENIA; and ACUTE RENAL FAILURE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noris, M | 1 |
| Ruggenenti, P | 1 |
| Todeschini, M | 1 |
| Figliuzzi, M | 1 |
| Macconi, D | 1 |
| Zoja, C | 1 |
| Paris, S | 1 |
| Gaspari, F | 1 |
| Remuzzi, G | 1 |
1 other study available for 3,4-methylenedioxyamphetamine and Hemolytic-Uremic Syndrome
| Article | Year |
|---|---|
Increased nitric oxide formation in recurrent thrombotic microangiopathies: a possible mediator of microvascular injury.
Topics: 3,4-Methylenedioxyamphetamine; Acute Disease; Adolescent; Adult; Arginine; Cells, Cultured; Chromato | 1996 |